Clinical Trial Update: A Study to Compare the Pharmacokinetics and Safety of Optivate® and Haemate P® in Patients With Von Willebrand Disease. [Phase 2]

View source ↗

Summary

Phase 2 trial comparing pharmacokinetics and safety of Optivate and Haemate P in patients with von Willebrand disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Von Willebrand Disease

Drugs mentioned

• Haemate P
• Optivate (von Willebrand factor concentrate (plasma-derived))

Snippet

Sponsor: Bio Products Laboratory | Conditions: vonWillebrand's Disease | Phase 2 | Status: COMPLETED